Edwards Lifesciences, TAVR and Stifel
In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...
Shares of Edwards Lifesciences Corp. advanced 4.86% to $72.56 Tuesday, on what proved to be an all-around great trading ...
Edwards Lifesciences Corp (EW) stock saw a decline, ending the day at $71.13 which represents a decrease of $-1.43 or -1.97% from the prior close of $72.56. The stock opened at $72.5 and touched a low ...
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...
Wolfe Research has recently reduced Edwards Lifesciences Corp (EW) stock to Underperform rating, as announced on January 16, 2025, according to Finviz. Earlier, on December 16, 2024, BofA Securities ...
Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...
EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.
Bullish option flow detected in Edwards Lifesciences (EW) with 4,815 calls trading, 1.4x expected, and implied vol increasing over 1 point to ...
Today, Benzinga's options scanner spotted 8 options trades for Edwards Lifesciences. This is not a typical pattern. The ...
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback